Proteomics International Laboratories (ASX:PIQ) validated the use of a plasma protein biomarker to detect endometriosis via the PromarkerEndo diagnosis test, according to a Monday filing with the Australian bourse.
A recent study showed that the test was able to separate healthy individuals with endometriosis patients using the biomarker, the filing said.
Results were published in the journal Human Reproduction, as per the filing.
The company's shares surged past 22% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。